Award

Outcomes following salpingectomy in BRCA1 and BRCA2 mutation carriers

Description: Women who inherit a BRCA1 or BRCA2 mutation face the highest known risk of developing ovarian cancer, a disease with a very poor prognosis. There are currently no effective methods to detect ovarian cancer at an early stage, and thus, these women are strongly advised to undergo preventive removal of their fallopian tubes and ovaries ('oophorectomy') at a young age (prior to age 45). There is evidence to suggest that some ovarian tumours actually begin in the fallopian tube rather than the ovary and that removing the fallopian tubes but not the ovaries ('salpingectomy') may prevent a subset of ovarian cancers. This has resulted in a dramatic change in clinical practice among women in the general population, where only fallopian tubes (not ovaries) are now removed at the time of hysterectomy or instead of tubal ligation. Since early surgical menopause in BRCA mutation carriers may be associated with unwanted side-effects such as the onset of menopausal symptoms and a decline in bone or brain health, there has also been increasing interest in salpingectomy in these women to simultaneously prevent disease but prevent menopause. This is of concern given that there is no evidence to support that salpingectomy will prevent ovarian cancer to the extent that we see with oophorectomy. Thus, we propose to use data from the largest cohort of BRCA mutation carriers that we have assembled to compare the risk of developing and dying of ovarian cancer among those with salpingectomy vs. oophorectomy. We will also evaluate what factors (personal, health care provider) influence the decision of women with a BRCA mutation. Our team is well-positioned to address these important scientific and clinical questions. Given the high fatality associated with ovarian cancer along with the extremely high lifetime risks in BRCA mutation carriers, it is imperative and timely that we evaluate whether 'salpingectomy' is equally effective as 'oophorectomy' before widespread uptake by these women.
Amount: CA$474,300
Funding type: research
Funder scheme: Project Grant
Start date: 2019-10-01
End date: 2024-09-30
Institutions: Women's College Hospital, Women's College Hospital (Toronto)
Subfield: Genetics
Funded outputs count: 0
Funder award ID: 165983_1
OpenAlex ID: G7111668642